Cleveland Clinic is touting itself as one of the few health centers in the country that’s offering a new stent from Covidien that’s designed to divert blood away from aneurysms.
Clinic surgeons have implanted the Pipeline Embolization Device, a flexible stent that’s placed in the carotid artery, in 12 patients thus far, The Plain Dealer reported.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Upon U.S. Food and Drug Administration approval of the device last year, Covidien hyped the Pipeline as a “new class” of embolization device.
That’s because the device works by redirecting blood flow away from the aneurysm to the undamaged part of the vessel and causes the blood that remains in the aneurysm to clot, which prevents the aneurysm from rupturing.
The device is used to treat adults with so-called “large or giant wide-necked brain aneurysms,” the type that are the hardest to treat and that historically have a poor long-term prognosis, according to The Plain Dealer.
Covidien picked up the Pipeline device as part of its $2.6 billion acquisition of Minnesota-based ev3 in 2010.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Covidien CEO Jose Almeida on Monday told analysts at the JP Morgan healthcare conference that the Pipeline device has seen “a tremendous amount of proliferation across the globe,” Mass Device reported.
“It’s doing a great job of pulling coil business into our basket,” Almeida said. “This product is taking off across the globe, China, everywhere.”
